Current Atherosclerosis Reports

, Volume 4, Issue 5, pp 363–372

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis

  • Eva Lonn

DOI: 10.1007/s11883-002-0074-7

Cite this article as:
Lonn, E. Curr Atheroscler Rep (2002) 4: 363. doi:10.1007/s11883-002-0074-7


Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) effectively interfere with the renin-angiotensin system and exert various beneficial actions on cardiac and vascular structure and function, beyond their blood pressure-lowering effects. Randomized, controlled clinical trials have shown that ACE inhibitors improve endothelial function, cardiac and vascular remodeling, retard the anatomic progression of atherosclerosis, and reduce the risk of myocardial infarction, stroke, and cardiovascular death. Therefore, these agents are recommended in the treatment of a wide range of patients at risk for adverse cardiovascular outcomes, including those with coronary disease, prior stroke, peripheral arterial disease, high-risk diabetes, hypertension, and heart failure. ARBs are effective blood pressure-lowering and renoprotective agents and can be used in heart failure in patients who do not tolerate ACE inhibitors. The role of ARBs in the prevention of atherosclerosis and its sequelae is currently under investigation. The use of combined ACE inhibitor plus ARB therapy offers theoretical advantages over the use of each of these agents alone and is also under investigation in large, randomized clinical trials.

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Eva Lonn
    • 1
  1. 1.Division of Cardiology and Population Health InstituteMcMaster University, Hamilton General HospitalHamiltonCanada

Personalised recommendations